RegeneRx Biopharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From RegeneRx Biopharmaceuticals, Inc.
The European Medicines Agency has added 13 new drugs to its list of products that are under review for potential pan-EU marketing approval.
Novo gets worldwide development and commercial rights except for Heartseed’s home market in Japan. LianBio unveils licensing partnerships with Lyra, Landos and Nanobiotix.
Samsung Bioepis reiterated that the US pharma market is “the most fragmented and the most complicated market in the world” as it discussed its biosimilar fortunes in Europe.
A bit late to the table, Lupin is exploring voluntary licensing for COVID-19 therapeutics and vaccines from Gilead’s remdesivir to Merck’s molnupiravir. Meanwhile, pricing for a biosimilar to Lucentis, which has been filed for approval in India, will be keenly watched.
- Large Molecule